The Financial Horizons
No Result
View All Result
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
  • Latest News
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
  • Latest News
No Result
View All Result
The Financial Horizons
No Result
View All Result
Home Stock

Elon Musk’s brain implant company Neuralink announces FDA approval of in-human clinical study

by
May 26, 2023
in Stock
0
Elon Musk’s brain implant company Neuralink announces FDA approval of in-human clinical study
0
SHARES
14
VIEWS
Share on FacebookShare on Twitter

Neuralink, the neurotech startup co-founded by Elon Musk, announced Thursday it has received approval from the Food and Drug Administration to conduct its first in-human clinical study.

Neuralink is building a brain implant called the Link, which aims to help patients with severe paralysis control external technologies using only neural signals. This means patients with severe degenerative diseases like ALS could eventually regain their ability to communicate with loved ones by moving cursors and typing with their minds.

“This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people,” the company wrote in a tweet.

The FDA and Neuralink did not immediately respond to CNBC’s request for comment. The extent of the approved trial is not known. Neuralink said in a tweet that patient recruitment for its clinical trial is not open yet.

Neuralink is part of the emerging brain-computer interface, or BCI, industry. A BCI is a system that deciphers brain signals and translates them into commands for external technologies. Neuralink is perhaps the best-known name in the space thanks to the high profile of Musk, who is also the CEO of Tesla, SpaceX and Twitter.

Scientists have been studying BCI technology for decades, and several companies have developed promising systems that they hope to bring to market. But receiving FDA approval for a commercial medical device is no small task — it requires companies to successfully conduct several extremely thorough rounds of testing and data safety collection.

No BCI company has managed to clinch the FDA’s final seal of approval. But by receiving the go-ahead for a study with human patients, Neuralink is one step closer to market.

Neuralink’s BCI will require patients to undergo invasive brain surgery. Its system centers around the Link, a small circular implant that processes and translates neural signals. The Link is connected to a series of thin, flexible threads inserted directly into the brain tissue where they detect neural signals.

Patients with Neuralink devices will learn to control it using the Neuralink app. Patients will then be able to control external mice and keyboards through a Bluetooth connection, according to the company’s website.

The FDA’s approval for an in-human study is a significant win for Neuralink after a series of recent hurdles at the company. In February, the U.S. Department of Transportation confirmed to CNBC that it had opened an investigation into Neuralink for allegedly packaging and transporting contaminated hardware in an unsafe manner. Reuters reported in March that the FDA had rejected Neuralink’s application for human trials, and reportedly outlined “dozens” of issues the company needed to address.

Neuralink has also come under fire from activist groups for its alleged treatment of animals. The Physician’s Committee for Responsible Medicine, which advocates against animal testing, has repeatedly called on Musk to release details about experiments on monkeys that had resulted in internal bleeding, paralysis, chronic infections, seizures, declining psychological health and death.

A representative for PCRM did not immediately respond to CNBC’s request for comment.

More from CNBC

Disney still has plans to spend billions in Florida despite its battle with DeSantis JPMorgan is developing a ChatGPT-like A.I. service that gives investment advice Ford EVs will use Tesla charging tech in surprise partnership between rival automakers

In addition to helping patients with paralysis, experts believe BCIs could someday help treat maladies like blindness and mental illness. Musk has expressed his intent for Neuralink to explore these future use cases, as well as potential applications for healthy people.

At a “show and tell” recruitment event late last year, Musk even claimed he plans to someday receive one of Neuralink’s implants himself.

“You could have a Neuralink device implanted right now and you wouldn’t even know,” Musk said at the time. “In fact, in one of these demos, I will.”

This post appeared first on NBC NEWS
Previous Post

German Economy Declined in the Q1 – What Lies Ahead?

Next Post

U.S. PCE data: tech stocks could ‘continue to run up’

Next Post
U.S. PCE data: tech stocks could ‘continue to run up’

U.S. PCE data: tech stocks could ‘continue to run up’

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent News

    Trump’s tariff strategy could pay for his tax bill, but only if they stick, experts warn

    Trump’s tariff strategy could pay for his tax bill, but only if they stick, experts warn

    June 6, 2025
    Trump not interested in talking to Musk: ‘Elon’s totally lost it’

    Trump not interested in talking to Musk: ‘Elon’s totally lost it’

    June 6, 2025
    Procter & Gamble to cut 7,000 jobs as part of broader restructuring

    Procter & Gamble to cut 7,000 jobs as part of broader restructuring

    June 6, 2025
    Claim Trump nixed top Musk ally from NASA post over Dem donations belied by ex-Dems on team

    Claim Trump nixed top Musk ally from NASA post over Dem donations belied by ex-Dems on team

    June 6, 2025
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: Thefinancialhorizons.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thefinancialhorizons.com | All Rights Reserved

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Editor’s Pick
    • Latest News

    Disclaimer: Thefinancialhorizons.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thefinancialhorizons.com | All Rights Reserved